There were errors in two sentences within the section 'Epigenetic changes in SCLC', indicating that EZH2 suppresses ASCL1 expression by suppression of TGFβ signalling. Instead, EZH2 promotes ASCL1 expression by suppression of TGFβ signalling. This has been corrected in the online and print versions of the article.
Additional information
The online version of the original article can be found at 10.1038/nrc.2017.87
Rights and permissions
About this article
Cite this article
Gazdar, A., Bunn, P. & Minna, J. Erratum: Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer 17, 765 (2017). https://doi.org/10.1038/nrc.2017.106
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrc.2017.106
This article is cited by
-
A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer
Scientific Reports (2024)
-
Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice
Cell Death Discovery (2023)
-
Targeting PEA3 transcription factors to mitigate small cell lung cancer progression
Oncogene (2023)
-
Genomic features of Chinese small cell lung cancer
BMC Medical Genomics (2022)
-
Heterogeneity of neuroendocrine transcriptional states in metastatic small cell lung cancers and patient-derived models
Nature Communications (2022)